FIELD: biotechnology.
SUBSTANCE: disclosed is a genetic construct for inducing the proliferation of peripheral monocytes and dendrite cells in vitro derived from human blood, comprising sequences coding transcription factors c-Mus and BMI1, as well as their binding self-splitting peptide sequence of Thosea asigna T2A virus, providing polycistronic expression of transcription factors under the control of one EF1alpha promoter. Said construct is derived from expression plasmid lentiviral vector pLEF1a-tagRFP, including a number of regulatory sequences: 5' and 3' LTR long end repeats, Rev dependent element (RRE or Rev-response element), Env is a regulatory sequence providing packaging of a viral genome into a viral particle structure with formation of a virion, cPRT - central polypurine path, a post-transcriptional regulatory element WPRE, an EF1alpha promoter.
EFFECT: invention provides effective constitutive expression of transcription factors s-Mus and BMI1 when introducing said construct into peripheral monocytes and dendritic cells.
1 cl, 3 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
AUXILIARY PLASMID LENTIVIRAL EXPRESSION VECTOR FOR OBTAINING HIGH TITERS OF Vpx-CONTAINING LENTIVIRAL PARTICLES, WHICH PROVIDES EFFECTIVE INFECTION OF HUMAN MONOCYTES AND DENDRITIC CELLS | 2017 |
|
RU2697781C2 |
EXPRESSION PLASMID LENTIVIRAL VECTOR FOR HETEROLOGICAL EXPRESSION OF HUMAN CD44 RECOMBINANT PROTEIN | 2015 |
|
RU2646111C2 |
EXPRESSIONAL PLASMID LENTIVIRAL VECTOR FOR HETEROLOGICAL EXPRESSION OF RECOMBINANT HUMAN PROTEIN CD47 | 2015 |
|
RU2627181C2 |
GENETIC CONSTRUCT CODING STRUCTURE OF T-CELL CHIMERIC RECEPTOR BASED ON SINGLE-CHAIN VHH ANTIBODIES SPECIFIC TO TUMOUR RECEPTOR CD47 FOR THE TARGETED IMMUNOTHERAPY OF MALIGNANT GROWTHS | 2017 |
|
RU2707535C2 |
METHOD FOR PRODUCING CYTOTOXIC T-LYMPHOCYTES EXPRESSING CHIMERIC RECEPTORS | 2018 |
|
RU2714380C1 |
RECOMBINANT LENTIVIRAL VECTOR, HOST CELL TRANSDUCED WITH LENTIVIRAL VECTOR, METHODS FOR TRANSDUCTION AND USES THEREOF | 2002 |
|
RU2305708C2 |
TRANSGENIC GENETIC LABELS AND METHODS OF USING | 2015 |
|
RU2729112C2 |
TRANSGENIC GENETIC LABELS AND METHODS OF USE | 2015 |
|
RU2822461C1 |
INSERTION OF TARGET GENE FOR IMPROVED CELLULAR IMMUNOTHERAPY | 2017 |
|
RU2824204C2 |
DOUBLE VECTOR FOR SUPPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS | 2010 |
|
RU2562868C2 |
Authors
Dates
2019-08-19—Published
2017-12-28—Filed